Foundation system

Prostate Cancer Foundation Announces First-Ever PCF-Pfizer Global Health Equity Challenge Award Winners

LOS ANGELES, California, April 29, 2022 – The Prostate Cancer Foundation (PCF) today announced 11 PCF-Pfizer Global Health Equity Challenge awards. A collaboration between PCF and Pfizer Global Medical Grants, the awards totaling $1.47 million are awarded to teams from some of the world’s leading cancer research institutions to support prostate cancer research projects that will improve understanding or reduce disparities in diagnosis, treatment, and patient outcomes in minority and underserved communities. The 11 winners represent eight countries, including Hong Kong, Ghana, Kenya, Malaysia, Nigeria, the United Republic of Tanzania, Uganda and the United States, and were selected by a panel of independent experts estimated collected by PCF.

Globally, prostate cancer is the second most commonly diagnosed form of cancer in men, with over 1.4 million cases diagnosed worldwide. In the United States alone, black men are about 75% more likely to be diagnosed with prostate cancer and more than twice as likely to die from it; in the Latin American community, prostate cancer is the most diagnosed cancer in men. The 11 projects selected from around the world in the 2021 PCF-Pfizer Global Health Equity Challenge Awards will focus specifically on research to identify barriers to the delivery of equitable health care and health services research agendas. to study and optimize the delivery of care.

“The Prostate Cancer Foundation has been funding research to understand and address this disparity for more than 25 years,” said Howard R. Soule, PhD, PCF’s executive vice president and chief scientific officer. “We are honored to partner with Pfizer in this endeavor and commend the researchers for their research which we believe has the potential to reduce disparities in prostate cancer.”

“At Pfizer, we are committed to reducing health care disparities by working with partners who share our vision of health equity and quality care for all,” said Dany Habr, MD, Chief Medical Officer from Pfizer Oncology. “Pfizer and the Prostate Cancer Foundation are steadfast in their support of these researchers and their work to address these critical areas of improvement for the prostate cancer community.

Award-winning teams PCF-Pfizer Health Equity Challenge Award 2021 are:

Principal Investigators: Theodore DeWeese, MD, Johns Hopkins University School of Medicine; Sara Alcorn, MD, MPH, PhD, Johns Hopkins University School of Medicine
Co-researchers: Anna LaVigne, MD, Johns Hopkins University School of Medicine; Jean Wright, MD Johns Hopkins University School of Medicine; Todd Adams, MD, Virginia Commonwealth University School of Medicine; Michael Van Wert, MSW, MPH, Johns Hopkins University School of Medicine
Project title: Radiotherapy deserts in prostate cancer: identifying regions where resources and needs do not match through characterizing the impact of race, poverty, and the rural-urban continuum on density and utilization radiation resources in the United States

Principal Investigator: Christina Dieli-Conwright, PhD, MPH, Dana-Farber Cancer Institute
Co-researchers: Paul Nguyen, MD, Dana-Farber Cancer Institute; Tim Rebbeck, PhD, Dana-Farber Cancer Institute; Hajime Uno, PhD, Dana-Farber Cancer Institute; Dong-Woo Kang, PhD; Dana-Farber Cancer Institute
Project title: Exercise to Improve Cardiovascular Health in Black Prostate Cancer Patients Treated with Androgen Deprivation: The POWER Trial

Principal Investigators: Veda Giri, MD, Thomas Jefferson University; Amy Leader, DrPH, MPH, Thomas Jefferson University
Co-researchers: Mary-Ellen Taplin, MD; Dana-Farber Cancer Institute; Brandon Mahal, MD, University of Miami Miller School of Medicine-Sylvester Comprehensive Cancer Center; Jessica Russo, LCGC, Thomas Jefferson University
Project title: Expanding Prostate Genetics Awareness, Navigation, and Administration: The EXPAND Network

Principal Investigator: Lindsey Herrel, MD, MS, University of Michigan
Co-researchers: Avinash Maganty, MD, University of Michigan; Brent Hollenbeck, MD, MS, University of Michigan; Vahakn Shahinian, MD, University of Michigan
Project title: Understanding the impact of dual eligibility on the treatment of localized prostate cancer

Principal Investigators: Patrick Maison, MBChB, Cape Coast Teaching Hospital, Ghana; Evelyn Jaige, MD, PhD, Henry Ford Health System
Co-researchers: George Amoah, MBChB, Komfo Anokye Teaching Hospital, Ghana; Sylvester Antwi, MD, Henry Ford Health System; Janet Acquaye, MS, precision medicine for aggressive breast cancer; Doreen Dankerlui, MS, Henry Ford Health System; Livingstone Aduse-Poku, MS, Precision Medicine for Aggressive Breast Cancer
Project title: Integrating orthodox and traditional prostate cancer care and treatment in Ghana

Principal Investigator: Blandina Mmbaga, MD, MMed, PhD, Kilimanjaro Christian Medical Centre, United Republic of Tanzania
Co-researchers: Kien Mteta, MD, MMed, MSc, Kilimanjaro Christian Medical University College; Alex Mremi, MMed, Kilimanjaro Christian Medical Center; Orgeness Mbwambo, MMed, Kilimanjaro Christian Medical University, Kilimanjaro Christian Medical Center; Bartholomeo Ngowi, MD, MMed, Kilimanjaro Christian Medical Center
Project title: Correlation between prostate cancer and PSA, community awareness and barriers associated with screening among men in northern Tanzania

Principal Investigator: Murallitharan Munisamy, MD, PhD, National Cancer Society Malaysia, Malaysia
Project title: GPS-P: Guided patient support navigation program for men with prostate cancer

Principal Investigator: Pius Musau, MBChB, MMed, MSc, PhD, Moi University, Eldoret-Kenya
Co-researchers: Edward Mugalo, MBChB, MMed, Moi University, Eldoret-Kenya; Walter Akello, BSc, MBChB, MMed, Egerton University, Njoro, Kenya; Dennis Rono, MBChB, MSc, MMed, Egerton University, Njoro-Kenya; Kibet Keitany, MBChB, MMed, Moi Teaching and Referral Hospital, Eldoret-Kenya; Samson Boyo, BBM, Moi Teaching and Referral Hospital, Eldoret-Kenya
Project title: Prostate Cancer Care in Western Kenya: Identifying Barriers to Care, Establishing and Interviewing Rapid Access Satellite Clinics, and Evaluating Measures Instituted for Better Outcomes

Principal Investigators: Jackson Orem, Uganda Cancer Institute, Uganda; Lyn Atuyambe, PhD, MPH, Makerere University
Co-researchers: Annabella Habinka Ejiri, PhD, MS, King Ceasor University; Alfred Jatho Lubega, PhD, MPH, Uganda Cancer Institute; Babra Nalwadda, DPH, King Ceasor University; Alphonsina Mujiwimana, MBChB, King Ceasor University; Sibointore Jack, MPH, Ugandan Prisons; Justine Ariko, MSc, Ugandan Prisons; Kajooba Fred, MBChB, Ugandan Prisons
Project title: Understand the barriers and facilitators to male prostate cancer screening in Ugandan prisons in order to design and implement interventions to increase the uptake of prostate cancer screening in prison settings

Principal Investigator: Marks Shek Nam Ng, RN, PhD, Chinese University of Hong Kong
Co-researchers: Ka Ming Chow, RN, RM, DN, FHKAN, Chinese University of Hong Kong; Kai Chow Choi, PhD, Chinese University of Hong Kong; Kath Schubach, RN, BSc, MN, Men’s Health Melbourne; Carmen Wing Han Chan, RN, PhD, FAAN, Chinese University of Hong Kong
Project title: Health inequalities in sexual health services among Chinese men with prostate cancer in public hospitals

Principal Investigator: Musliu Tolani, MBBS, PGcertPH FWACS, FMCS, Ahmadu Bello University, Nigeria
Co-researchers: Ahmed Muhammed, MBBS, FMCS, Ahmadu Bello University; Agbo Christian Agbo, MBBS, FMCS, Dalhatu Araf Specialty Hospital; Rufus Wale Ojewola, MBChB, FWACS, FMCS, MPH, University of Lagos; Ernie Kaninjing, DrPH, MPH, MBA, CHES, Georgia College & State University; Rebecca DeBoer, MD, MA, University of California, San Francisco
Project title: Using an implementation science approach to develop and evaluate a systems-strengthening intervention for the clinically localized management of prostate cancer in a low-middle-income country in sub-Saharan Africa

The Prostate Cancer Foundation (PCF) is the world’s leading philanthropic organization dedicated to funding vital prostate cancer research. Founded in 1993 by Mike Milken, PCF has been responsible for raising nearly $1 billion to support cutting-edge research through more than 2,200 research projects at 245 leading cancer centers in 28 countries around the world. Since PCF’s inception and thanks to its efforts, patients around the world are living longer, suffering fewer complications and enjoying a better quality of life. PCF is committed to creating a global public square for prostate cancer, in service of our mission to end death and suffering from the disease. Learn more at

# # #


Staci L. Vernick Kathy Vincent
Prostate Cancer Foundation For the Prostate Cancer Foundation
[email protected] [email protected]